Microvascular Complications of Diabetes Mellitus: Renal Protection Accompanies Cardiovascular Protection

被引:60
作者
Brown, W. Virgil [1 ]
机构
[1] Emory Univ, Sch Med, Atlanta, GA USA
关键词
D O I
10.1016/j.amjcard.2008.09.068
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The microvascular complications of diabetes mellitus confer substantial morbidity and impair patient quality of life. Dyslipidemia and prolonged hyperglycemia promote an increase in oxidative stress, inflammation, and vascular damage, which together promote endothelial dysfunction and are associated with macrovascular and microvascular complications. Microalbuminuria is an early marker of diabetic nephropathy and an independent risk factor for cardiovascular disease. Diabetic nephropathy is the most common cause of end-stage renal disease in developed countries, and its prevalence is increasing. Preventing or limiting the progression of diabetic nephropathy, as demonstrated in the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) trial, may prevent or delay renal complications, as well as convey important cardioprotective benefits in patients with type 2 diabetes. (c) Published by Elsevier Inc. (Am J Cardiol 2008;102[suppl]:10L-13L)
引用
收藏
页码:10L / 13L
页数:4
相关论文
共 29 条
[1]   Standards of medical care in diabetes 2008 [J].
不详 .
DIABETES CARE, 2008, 31 :S12-S54
[2]   Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: Results from the Diabetes Atherosclerosis Intervention Study (DAIS) [J].
Ansquer, JC ;
Foucher, C ;
Rattier, S ;
Taskinen, MR ;
Steiner, G .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2005, 45 (03) :485-493
[3]   Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia [J].
Athyros, VG ;
Papageorgiou, AA ;
Athyrou, VV ;
Demitriadis, DS ;
Kontopoulos, AG .
DIABETES CARE, 2002, 25 (07) :1198-1202
[4]   FORMATION OF IMMUNOCHEMICAL ADVANCED GLYCOSYLATION END-PRODUCTS PRECEDES AND CORRELATES WITH EARLY MANIFESTATIONS OF RENAL AND RETINAL DISEASE IN DIABETES [J].
BEISSWENGER, PJ ;
MAKITA, Z ;
CURPHEY, TJ ;
MOORE, LL ;
JEAN, S ;
BRINCKJOHNSEN, T ;
BUCALA, R ;
VLASSARA, H .
DIABETES, 1995, 44 (07) :824-829
[5]   The pathobiology of diabetic complications - A unifying mechanism [J].
Brownlee, M .
DIABETES, 2005, 54 (06) :1615-1625
[6]   Primary prevention of cardiovascular diseases in people with diabetes mellitus - A scientific statement from the American Heart Association and the American Diabetes Association [J].
Buse, John B. ;
Ginsberg, Henry N. ;
Bakris, George L. ;
Clark, Nathaniel G. ;
Costa, Fernando ;
Eckel, Robert ;
Fonseca, Vivian ;
Gerstein, Hertzel C. ;
Grundy, Scott ;
Nesto, Richard W. ;
Pignone, Michael P. ;
Plutzky, Jorge ;
Porte, Daniel ;
Redberg, Rita ;
Stitzel, Kimberly F. ;
Stone, Neil J. .
CIRCULATION, 2007, 115 (01) :114-126
[7]   Acceleration of diabetic renal injury in the superoxide dismutase knockout mouse: effects of tempol [J].
DeRubertis, Frederick R. ;
Craven, Patricia A. ;
Melhem, Mona F. .
METABOLISM-CLINICAL AND EXPERIMENTAL, 2007, 56 (09) :1256-1264
[8]   Cardiovascular disease and subsequent kidney disease [J].
Elsayed, Essam F. ;
Tighiouart, Hocine ;
Griffith, John ;
Kurth, Tobias ;
Levey, Andrew S. ;
Salem, Deeb ;
Sarnak, Mark J. ;
Weiner, Daniel E. .
ARCHIVES OF INTERNAL MEDICINE, 2007, 167 (11) :1130-1136
[9]   Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes [J].
Gaede, P ;
Vedel, P ;
Larsen, N ;
Jensen, GVH ;
Parving, H ;
Pedersen, O .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (05) :383-393
[10]   Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria:: the Steno type 2 randomised study [J].
Gæde, P ;
Vedel, P ;
Parving, HH ;
Pedersen, O .
LANCET, 1999, 353 (9153) :617-622